» Articles » PMID: 35903578

Development and Validation of a Nomogram for the Prediction of Unfavorable Treatment Outcome Among Multi-Drug Resistant Tuberculosis Patients in North West Ethiopia: An Application of Prediction Modelling

Overview
Publisher Dove Medical Press
Date 2022 Jul 29
PMID 35903578
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multidrug-resistant tuberculosis (MDR-TB) is a global problem and a health security threat, which makes "Ending the global TB epidemic in 2035" unachievable. Globally, the unfavourable treatment outcome remains unacceptably high. Therefore, this study aimed to develop a risk prediction model for unfavorable treatment outcomes in MDR-TB patients, which can be used by clinicians as a simple clinical tool in their decision-making.

Objective: The objective of this study was to develop and validate a risk prediction model for the prediction of unfavorable treatment outcomes among MDR-TB patients in North-West Ethiopia.

Methods: We used MDR-TB data collected from the University of Gondar and Debre Markos referral hospitals. A retrospective follow-up study was conducted and a total of 517 patients were included in the study. STATA version 16 statistical software and R version 4.0.5 were used for the analysis. Descriptive statistics were carried out. A multivariable model was fitted using all potent predictors selected by the lasso regression method. A simplified risk prediction model (nomogram) was developed based on the binomial logit-based model, and its performance was described by assessing its discriminatory power and calibration. Finally, decision curve analysis (DCA) was done to evaluate the clinical and public health impact of the developed model.

Results: The developed nomogram comprised six predictors: baseline anemia, major adverse event, comorbidity, age, marital status, and treatment supporter. The model has a discriminatory power of 0.753 (95% CI: 0.708, 0.798) and calibration test of (P-value = 0.695). It was internally validated by bootstrapping method, and it has a relatively corrected discrimination performance (AUC = 0.744, 95CI: 0.699, 0.788). The optimism coefficient was found to be 0.009. The decision curve analysis showed the net benefit of the model as threshold probabilities varied.

Conclusion: The developed nomogram can be used for individualized prediction of unfavorable treatment outcomes in MDR-TB patients for it has a satisfactory level of accuracy and good calibration. The model is clinically interpretable and was found to have added benefits in clinical practice.

Citing Articles

Predictors of early and interim culture un-conversion in multidrug-resistant/rifampicin-resistant tuberculosis: a retrospective multi-center cohort study in China.

Chen Q, He W, Du J, Kang W, Zou L, Tang X Antimicrob Resist Infect Control. 2024; 13(1):126.

PMID: 39407338 PMC: 11481364. DOI: 10.1186/s13756-024-01480-8.


Treatment Outcomes and Associated Influencing Factors Among Patients with Rifampicin-Resistant Tuberculosis: A Multicenter, Retrospective, Cohort Study in China.

Zou L, Kang W, Guo C, Du J, Chen Q, Shi Z Infect Drug Resist. 2024; 17:3737-3749.

PMID: 39221187 PMC: 11366237. DOI: 10.2147/IDR.S467971.


Predicting the individualized risk of human immunodeficiency virus infection among sexually active women in Ethiopia using a nomogram: prediction model development and validation.

Tesfie T, Yehuala T, Agimas M, Yismaw G, Maru Wubante S, Fente B Front Public Health. 2024; 12:1375270.

PMID: 38979038 PMC: 11229785. DOI: 10.3389/fpubh.2024.1375270.


Prognostication of treatment non-compliance among patients with multidrug-resistant tuberculosis in the course of their follow-up: a logistic regression-based machine learning algorithm.

Anley D, Akalu T, Dessie A, Anteneh R, Zemene M, Bayih W Front Digit Health. 2023; 5:1165222.

PMID: 37228302 PMC: 10203954. DOI: 10.3389/fdgth.2023.1165222.


A Scoring System Based on Laboratory Parameters and Clinical Features to Predict Unfavorable Treatment Outcomes in Multidrug- and Rifampicin-Resistant Tuberculosis Patients.

Yan J, Luo H, Nie Q, Hu S, Yu Q, Wang X Infect Drug Resist. 2023; 16:225-237.

PMID: 36647452 PMC: 9840374. DOI: 10.2147/IDR.S397304.

References
1.
Arroyo L, Ramos A, Yamamura M, Berra T, Alves L, Belchior A . Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis. Rev Saude Publica. 2019; 53:77. PMC: 6752648. DOI: 10.11606/s1518-8787.2019053001151. View

2.
Verdecchia M, Keus K, Blankley S, Vambe D, Ssonko C, Piening T . Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011-2013. PLoS One. 2018; 13(10):e0205601. PMC: 6192624. DOI: 10.1371/journal.pone.0205601. View

3.
Madan C, Chopra K, Satyanarayana S, Surie D, Chadha V, Sachdeva K . Developing a model to predict unfavourable treatment outcomes in patients with tuberculosis and human immunodeficiency virus co-infection in Delhi, India. PLoS One. 2018; 13(10):e0204982. PMC: 6169917. DOI: 10.1371/journal.pone.0204982. View

4.
Alene K, Viney K, McBryde E, Tsegaye A, Clements A . Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health. 2016; 22(3):351-362. DOI: 10.1111/tmi.12826. View

5.
Oliveira O, Gaio R, Correia-Neves M, Rito T, Duarte R . Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000-2016. PLoS One. 2021; 16(4):e0250028. PMC: 8057584. DOI: 10.1371/journal.pone.0250028. View